Investigational; no approved trade name identified as of 2026-09-27. Enicepatide and CT-388 identify the same compound.
Roche · Current owner/developer following the Carmot acquisition; enicepatide was previously designated CT-388.; Carmot Therapeutics · Originator of CT-388; acquired into Roche's Pharmaceuticals Division.; Zealand Pharma · Partner for the fixed-dose combination with petrelintide; this partnership does not identify Zealand as owner of enicepatide monotherapy.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Activates GLP-1 and GIP receptors with signaling biased toward cAMP.
Structure not yet verified
Structure not verified
Activates GLP-1 and GIP receptors with signaling biased toward cAMP.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.
Selected milestones only. This review adds the diabetes topline and its registry timing discrepancy; earlier development coverage remains incomplete. The plotted obesity results and earlier diabetes cohort keep their original study populations, analyses and review dates.
Roche acquisition completion announced
Carmot announced completion of its acquisition by Roche, including its CT-388 portfolio asset.
The posted CT-388-104 record (NCT06628362) lists weight and HbA1c changes at week 36 as co-primary outcomes, with week-48 changes secondary. This differs from Roche’s subsequent September 22 description of week-48 co-primary outcomes. The discrepancy remains unresolved; the registry update date is not a results date.
In CT-388-104, 447 adults with type 2 diabetes and overweight or obesity were randomized to enicepatide or placebo. Roche reports a 2.65-percentage-point HbA1c decrease from 8.1% and 15.5% weight loss at 24 mg after 48 weeks. Placebo values, intervals, arm denominators and estimand were not provided. Adverse-event discontinuation was 2.0% across active doses versus 0% with placebo; gastrointestinal events predominated. The primary-endpoint timing conflict with the registry is unresolved, so this result has not been added to the comparison plots. Phase 3 diabetes and cardiovascular-outcome trials are planned for the first half of 2027.